PCSK9 and stroke disorder: Meta-analysis of recent randomized clinical trials revealed promising results regarding the efficacy of PCSK9 inhibitors reducing the incidence of stroke by 25%, highlighting the potential of PCSK9 inhibitors as valuable additions to the current armamentarium for cerebrovascular risk reduction (33, 34).